Basilea Begins Phase 2a Expansion Trial Testing BAL101553 in Ovarian, Brain Cancers

Basilea Begins Phase 2a Expansion Trial Testing BAL101553 in Ovarian, Brain Cancers
Basilea Pharmaceutica has dosed its first patient in the expansion part of its Phase 1/2 trial (NCT02895360), which continues to explore the safety and effectiveness of BAL101553, an investigational tumor checkpoint controller, for the treatment of glioblastoma and ovarian cancer. The open-label Phase 2a expansion is designed to include up to 40 patients with either recurrent glioblastoma

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *